stockrow
Friday 6 November 2026
Export DXCM’s income statement to Excel — free account
DexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
- Revenue
- +11.2%
- EPS
- 0.00%
- Free cash flow
- −52.9%
- Total debt
- +0.31%
Quarter to September 2026, against a year earlier
79.50
4.96
−5.87%
Follow DXCM
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
30.87 | 26.17 | 26.00 | 33.32 |
P/S ratio |
5.56 | 5.02 | 5.18 | 6.33 | |
P/FCF ratio |
24.04 | 16.92 | 18.32 | 29.44 | |
P/Operating CF |
88.09 | 46.01 | 95.62 | 99.30 | |
P/B ratio |
9.43 | 8.18 | 9.82 | 12.75 | |
Price to Tangible BV |
9.77 | 8.43 | 10.31 | 13.35 | |
EV/Sales |
5.56 | 4.94 | 5.19 | 6.37 | |
EV/EBITDA |
22.27 | 18.40 | 18.39 | 21.70 | |
EV/Operating CF |
17.99 | 13.34 | 14.76 | 23.00 | |
EV/FCF |
24.06 | 16.64 | 18.37 | 29.62 | |
Quick Ratio |
1.50 | 1.58 | 1.36 | 1.33 | |
Current Ratio |
1.88 | 1.95 | 1.73 | 1.74 | |
Net Debt/EBITDA |
(1.95) | (3.64) | (1.82) | (1.43) | |
Debt/Assets |
19.57% | 18.72% | 19.25% | 19.93% | |
Debt/Equity |
0.45 | 0.42 | 0.47 | 0.49 | |
Asset Turnover |
0.73 | 0.72 | 0.72 | 0.74 | |
Operating CF/Net income |
1.10 | 2.63 | 1.08 | 1.18 | |
Capex/Depreciation |
(1.56) | (1.14) | (1.24) | (0.71) | |
Research and Development Expense of Revenue |
11.77% | 12.19% | 11.69% | 12.02% | |
Selling, General and Administrative Expense of Revenue |
25.52% | 29.34% | 27.42% | 27.94% | |
Intangible Assets out of Total Assets |
0.02 | 0.01 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
2.78% | 3.63% | 2.98% | 2.74% | |
Graham Net Nets |
0.02 | 0.03 | 0.01 | 0.01 | |
Graham Number |
18.45 | 20.36 | 19.99 | 19.86 | |
Earnings Yield |
3.24% | 3.82% | 3.85% | 3.00% | |
Free Cash Flow Yield |
4.16% | 5.91% | 5.46% | 3.40% | |
Revenue per Share |
3.23 | 3.10 | 3.42 | 3.59 | |
Operating CF per Share |
0.75 | 1.36 | 0.70 | 0.87 | |
Capex per Share |
(0.26) | (0.20) | (0.22) | (0.14) | |
Free Cash Flow per Share |
0.49 | 1.17 | 0.48 | 0.73 | |
Cash per Share |
5.12 | 6.27 | 5.09 | 4.85 | |
Shareholders Equity per Share |
7.04 | 7.68 | 6.86 | 6.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.04 | 7.68 | 6.86 | 6.77 | |
Free Cash Flow |
192.10 | 449.00 | 184.50 | 272.70 | |
Working Capital |
1,890.80 | 2,107.90 | 1,728.90 | 1,663.40 | |
Capital Expenditures |
(101.90) | (76.60) | (84.70) | (52.90) | |
Net Current Asset Value |
439.40 | 655.30 | 252.70 | 212.60 | |
EV/EBIT |
28.42 | 23.01 | 22.66 | 26.58 | |
Capex to Sales |
0.08 | 0.06 | 0.06 | 0.04 | |
Price to Operating Income |
28.40 | 23.40 | 22.60 | 26.42 | |
| Other line items | |||||
Average Receivables |
1,110.90 | 1,121.90 | 1,303.25 | 1,147.90 | |
Average Payables |
1,764.55 | 1,882.25 | 2,067.65 | 1,999.00 | |
Average Inventory |
585.85 | 615.90 | 648.55 | 687.40 | |
Average Assets |
6,412.20 | 6,692.50 | 6,891.15 | 6,869.40 | |
Average Common Equity |
2,424.30 | 2,611.75 | 2,597.25 | 2,630.75 |
Columns are period end dates · fundamentals updated 5 Nov 2026